Nidanilimab - CAS 2171061-85-9

Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

Interleukin, IL Receptor

Immunology/Inflammation

2170967

>95%

-20°C

Ice Packs

Inhibitory Antibodies